Dysregulated mitogen-activated protein kinase signalling as an oncogenic basis for clear cell sarcoma of the kidney

Area of Science:

• Paediatric oncology
• Molecular pathology
• Cancer genetics

Background:

• Clear cell sarcoma of the kidney (CCSK) is a rare paediatric renal malignancy with poorly understood oncogenic mechanisms.
• Current therapies rely on doxorubicin, which has significant cardiotoxic side effects.
• The YWHAE-NUTM2 gene fusion, resulting from a t(10;17) translocation, is the only recurrent genetic aberration identified in CCSK.

Purpose of the Study:

• To investigate the oncogenic role of the YWHAE-NUTM2 fusion transcript in CCSK.
• To explore the downstream signalling pathways affected by YWHAE-NUTM2 expression.
• To identify potential therapeutic targets for CCSK.

Main Methods:

• Generation of stably transfected cell lines with doxycycline-inducible YWHAE-NUTM2 expression.
• Assessment of cell migration using in vitro assays.
• Gene and protein expression analysis to identify dysregulated signalling pathways.
• Inhibition of MAPK/PI3K-AKT pathways using neutralizing antibodies.

Main Results:

• YWHAE-NUTM2-expressing cells demonstrated significantly increased cell migration.
• Dysregulation of MAPK/PI3K-AKT signalling pathways was observed in cells expressing the fusion transcript.
• Inhibition of MAPK/PI3K-AKT pathways abrogated the enhanced migratory phenotype.
• CCSK tumour samples showed similar up-regulation and activation of these signalling pathways.

Conclusions:

• The YWHAE-NUTM2 fusion transcript plays an oncogenic role in CCSK development and progression.
• MAPK/PI3K-AKT signalling pathways are critical downstream mediators of YWHAE-NUTM2-driven oncogenesis.
• Targeting these pathways presents a promising strategy for novel therapeutic interventions in CCSK.